Full Press Release Details
Skyline Medical Announces Results for
Third Quarter and First Nine Months of 2014
Increased STREAMWAY sales provide
Company with record three and nine month revenues
MINNEAPOLIS, MN - November 12, 2014
- Skyline Medical Inc. (OTCQB: SKLND) (the "Company"), the producer of the FDA approved STREAMWAY System for
automated, direct-to-drain surgical fluid disposal that reduces the risk of exposure to hazardous waste, today reported its results
for the third quarter and nine months ended September 30, 2014.
Third quarter revenues rose to $397,254,
up more than 268% compared to $107,835 for the third quarter in 2013. Year to date revenues rose to $785,767, compared to revenues
of $386,418 year to date in 2013. Gross profit for the third quarter of 2014 was up 221% to $262,528, compared to $81,654 for the
same period in 2013. The revenue in the first nine months of 2014 included the sale of 43 STREAMWAY systems. Three STREAMWAY Systems
were sold under the Company's pay per procedure plan whereby hardware revenue is recognized on a per procedure basis.
Net loss for the third quarter of 2014
was ($1.12) million, or ($0.37) per diluted share, compared to net loss of ($3.97) million, or ($2.18) per diluted share, in the
comparable period in 2013 (per share numbers are provided on a post-reverse split basis). The decrease in net loss was primarily
driven by a decrease in General and Administrative and Operating expenses.
"The quality of the STREAMWAY product
is evidenced by the amount of repeat business generated from existing customers and we are encouraged by the gradual sequential
growth we have seen throughout 2014 as the adoption rate steadily increases," said Josh Kornberg, CEO of Skyline Medical.
"Hospitals and medical facilities have been using canister based disposal methods for many years. We are therefore very aware
that we need to raise awareness of the major safety and cost benefits of using the automated STREAMWAY System in order to encourage
hospitals to move away from the status quo."
Kornberg added, "To facilitate this,
we continued to build our sales network by signing up two new independent contract groups to help the Company penetrate the Midwest
and Southeast, as well as an independent distributor in New York. We favor this approach to revenue generation because it enables
us to expand our footprint while keeping control of costs."
About Skyline Medical Inc.
Skyline Medical Inc. produces a fully automated,
patented, FDA cleared, surgical fluid disposal system that virtually eliminates operating room workers' exposure to blood, irrigation
fluid and other potentially infectious fluids found in the surgical environment. Today's manual surgical fluid handling methods
of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and is not an optimal approach
to the handling of surgical fluid waste. Skyline Medical's STREAMWAY(TM) System fully automates the collection, measurement
and disposal of surgical fluids and is designed to result in: 1) reducing overhead costs to hospitals and surgical centers, 2)
improving Occupational State and Health Association (OSHA) and other regulatory compliance agencies' safety concerns, and 3) streamlining
the efficiency of the operating room (and thereby making surgeries more profitable).
Skyline Medical's STREAMWAY System
is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease
infected canisters go to landfills annually in the United States. These tainted canisters can remain in landfills for years to
come. With the installation of Skyline Medical's STREAMWAY System, the number of canisters can be significantly reduced.
Skyline Medical Inc.'s STREAMWAY System is designed to make the operating room and our environment safer, cleaner, and better.
Skyline Medical products are currently being represented by independent professional sales representatives that cater to the needs
of hospitals and ambulatory surgical centers across the country. For additional information, please visit: www.skylinemedical.com.
Forward-looking Statements
Certain of the matters discussed in
this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business
that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties
include, among other things, inability to raise sufficient additional capital to operate our business; approximately $5.1 million
in debts, liabilities and cash obligations that predominantly become due early in calendar 2015; unexpected costs and operating
deficits, and lower than expected sales and revenues, if any; uncertain willingness and ability of customers to adopt new technologies
and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely
that we will ever become profitable, adverse economic conditions; adverse results of any legal proceedings; the volatility of our
operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales
and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process,
as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's
ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into
agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance
of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other
risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange
Commission, which are available for review at www.sec.gov. This is not a solicitation to buy or sell securities and does not purport
to be an analysis of the company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent
reports and other filings at www.sec.gov.
Skyline Investor Relations Contacts:
Phil Carlson / Elizabeth Barker
KCSA Strategic Communications
212-896-1233 / 212-896-1203
SOURCE: Skyline Medical Inc.
SKYLINE MEDICAL INC.
(A DEVELOPMENT STAGE COMPANY)
CONDENSED STATEMENTS OF OPERATIONS
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Revenue | $ | 397,254 | $ | 107,835 | $ | 785,767 | $ | 386,418 | ||||||||
| Cost of goods sold | 134,725 | 26,181 | 264,173 | 135,120 | ||||||||||||
| Gross Margin | 262,528 | 81,654 | 521,593 | 251,298 | ||||||||||||
| General and administrative expense | 737,519 | 3,195,589 | 3,247,023 | 5,906,805 | ||||||||||||
| Operations expense | 183,154 | 354,027 | 740,012 | 763,422 | ||||||||||||
| Sales and marketing expense | 325,141 | 164,712 | 849,364 | 357,274 | ||||||||||||
| Interest expense | 131,935 | 407,516 | 164,962 | 629,722 | ||||||||||||
| Loss (gain) on valuation of equity-linked financial instruments | - | (65,287 | ) | (11,599 | ) | (153,960 | ) | |||||||||
| Total expense | 1,377,749 | 4,056,557 | 4,989,763 | 7,503,263 | ||||||||||||
| Net income (loss) available to common shareholders | $ | (1,115,221 | ) | $ | (3,974,903 | ) | $ | (4,468,170 | ) | $ | (7,251,965 | ) | ||||
| Loss per common share basic and diluted | $ | (0.37 | ) | $ | (2.18 | ) | $ | (1.51 | ) | $ | (4.30 | ) | ||||
| Weighted average shares used in computation, basic and diluted | 2,984,335 | 1,821,006 | 2,967,483 | 1,687,625 |
SKYLINE MEDICAL INC.
(A DEVELOPMENT STAGE COMPANY)
CONDENSED BALANCE SHEETS
| 30-Sep-14 | 31-Dec-13 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash | $ | 244,044 | $ | 101,953 | ||||
| Accounts Receivable | 238,604 | 97,245 | ||||||
| Inventories | 315,620 | 122,175 | ||||||
| Prepaid Expense and other assets | 148,950 | 60,588 | ||||||
| Total Current Assets | 947,218 | 381,961 | ||||||
| Fixed Assets, net | 216,946 | 158,110 | ||||||
| Intangibles, net | 72,701 | 53,355 | ||||||
| Total Assets | $ | 1,236,865 | $ | 593,426 | ||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | 1,577,818 | 1,062,108 | ||||||
| Accrued expenses | 2,089,885 | 2,057,957 | ||||||
| Short-term note payable net of discounts of $353,583 and $0 (See Note 4) | 1,169,677 | 280,000 | ||||||
| Deferred Revenue | 5,000 | 69,000 | ||||||
| Total Current Liabilities | 4,842,380 | 3,469,065 | ||||||
| Accrued Expenses | 229,318 | 331,216 | ||||||
| Liability for equity-linked financial instruments (See Note 8) | - | 11,599 | ||||||
| Total Liabilities | $ | 5,071,698 | $ | 5,071,698 | ||||
| Commitments and Contingencies | - | - | ||||||
| Stockholders' Deficit: | ||||||||
| Series A Convertible Preferred Stock, $.01 par value, $100 Stated Value, 40,000 authorized, 20,550 outstanding | 206 | - | ||||||
| Common stock, $.01 par value, 10,666,667 authorized, 2,999,386 and 2,932,501 outstanding | 29,993 | 29,325 | ||||||
| Additional paid-in capital | 29,380,273 | 25,449,636 | ||||||
| Deficit accumulated during development stage | (33,245,305 | ) | (28,697,415 | ) | ||||
| Total Stockholders' Deficit | (3,834,833 | ) | (3,218,453 | ) | ||||
| Total Liabilities and Stockholders' Deficit | $ | 1,236,865 | $ | 593,426 |